Trial Profile
A retrospective study comparing combination therapy with infliximab or adalimumab and an immunosuppressive agent versus monotherapy in patients with inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary)
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 24 Aug 2015 New trial record